FVIIA FIBER-FACTOR WITH THE INCREASED PERIOD OF SURGERY FOR PREVENTION AND TREATMENT OF BLEEDING, AND ITS DOSAGE REGIMES

摘要

The present invention relates to dosing regimens with half-life extended Factor VIIa (FVIIa) for prophylactic and “on-demand” treatment of bleeding, as well as for preventing a bleeding episode during or after surgery in patients with congenital or acquired bleeding disorders. The present invention further relates to the use of half-life extended FVIIa for treating or preventing blood loss in patients without bleeding disorders in situations of hemorrhage, i.e., due to trauma or surgery. Another aspect of the invention is the treatment of acquired haemophilia.